The massive share dilution (shares outstanding up 4x in two weeks) significantly offsets the positive cash and compliance news. Monitor the upcoming 10-Q for actual revenue figures and cash burn rate — the 500%+ growth guidance is unverifiable and comes from a company with a history of negative stock performance. The stock's micro-cap status and low liquidity amplify volatility risk.
Price Chart
Executive Summary
VivoSim Labs filed an 8-K announcing it regained Nasdaq compliance (Rule 5550(b)(1) minimum equity), reported ~$10.1M cash on hand, and reiterated 500%+ FY2027 revenue growth guidance. The positive listing news and cash position are offset by massive share dilution (shares outstanding surged from 3.2M to 13.4M) and the lack of reported operating results, making this a mixed signal for a micro-cap biotech with a history of poor stock performance.
Key Facts
- Regained compliance with Nasdaq Listing Rule 5550(b)(1) (minimum $2.5M stockholders' equity)
- Preliminary cash on hand of ~$10.1M as of August 3, 2026
- Received $5.0M milestone payment from Eli Lilly and $1.0M released from escrow related to FXR program sale
- Completed a July 17, 2026 financing: gross proceeds $4.0M, net proceeds ~$3.6M from pre-funded and common warrants at $0.85/share
- Shares outstanding surged from 3,194,295 (June 30, 2026) to 13,390,789 (August 3, 2026) — 9,896,718 shares issued on warrant exercises
- Reiterated guidance for 500%+ revenue growth in Fiscal Year 2027
Financial Impact
Cash position improved to ~$10.1M from prior quarter's $364K equity; $9.0M in total cash inflows from Lilly ($6M) and warrant financing ($3.6M net). Share count increased 319% in two weeks.
Risk Factors
- Extreme dilution: share count increased from 3.2M to 13.4M in two weeks, massively diluting existing holders
- 500%+ revenue growth guidance is unverifiable forward-looking statement from a company with no reported current revenue in this filing
- No actual operating results (revenue, EPS) were reported in this filing — only cash position and guidance
- Micro-cap ($6M market cap) with low liquidity and high bankruptcy risk profile
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336844 |
| Document: vivs-ex99_1.htm | 0001193125-26-336844 |
| Document: 0001193125-26-336844-index-headers.html | 0001193125-26-336844 |
| Document: 0001193125-26-336844-index.html | 0001193125-26-336844 |
| Document: 0001193125-26-336844.txt | 0001193125-26-336844 |
| 8-K Data (Synthetic) | 0001193125-26-336844 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | 8-K | $0.1575 | awaiting T+20 | — | $0.1489 (+5.46%) |
Oct 6, 2026 19d ago | 8-K | $0.1915 | awaiting T+20 | — | $0.1489 (−22.25%) |
Sep 16, 2026 5w ago | Press Release | $0.2621 $0.1742 | ▼ −33.54% | ▼ −36.71% | $0.1489 (−43.19%) |
Aug 11, 2026 10w ago | EFFECT | $0.3526 $0.2750 | ▲ +22.01% | ▲ +20.95% | $0.1489 (+57.77%) |
Aug 6, 2026 11w ago | 8-K | $0.3299 $0.2790 | ▼ −15.43% | ▼ −16.03% | $0.1489 (−54.87%) |
Jul 17, 2026 14w ago | 8-K | $0.5790 $0.3225 | ▲ +44.30% | ▲ +48.75% | $0.1489 (+74.28%) |
Apr 3, 2026 29w ago | 8-K | $1.71 $1.41 | ▼ −17.54% | ▼ −26.53% | $0.1489 (−91.29%) |
Apr 1, 2026 29w ago | Press Release | $1.62 $1.44 | ▲ +11.11% | ▲ +20.83% | $0.1489 (+90.81%) |
Apr 1, 2026 29w ago | EFFECT | $1.62 $1.44 | ▼ −11.11% | ▼ −20.83% | $0.1489 (−90.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers